EMVision Medical Devices (ASX:EMV) has strengthened its growth trajectory with firm commitments for a $12 million capital raising, receiving strong backing from institutional, sophisticated, and professional investors.
The raise was supported by strategic shareholder Keysight Technologies, which subscribed pro rata under the total placement, underscoring its confidence in EMVision’s long-term vision.
The funds will accelerate major milestones across financial years 2026 and 2027, including advancing EMVision’s flagship emu in-hospital stroke imaging device toward FDA submission and initial commercialisation, and progressing its First Responder program through clinical trials, production readiness, and regulatory preparation.
To complement the placement, EMVision will also launch a Share Purchase Plan (SPP) for eligible retail shareholders, offering up to $30,000 worth of shares on the same terms, with free attaching options included.
EMVision CEO and Managing Director, Scott Kirkland, said the raise highlights strong investor confidence in the company’s mission. “We are delighted to receive the ongoing support of our existing shareholder base, including Keysight Technologies, and to welcome new institutional and sophisticated investors. These funds allow EMVision to progress our clinical, regulatory and go-to-market activities, while maintaining a strong balance sheet as we advance towards market access and commercialisation,” he said.
Barrenjoey Markets and Bell Potter Securities jointly led the placement.
With its portable, non-invasive neurodiagnostic devices, EMVision is working to reimagine how stroke and other time-critical medical conditions can be diagnosed and treated at the point of care. The company’s technologies aim to transform patient outcomes by delivering rapid, accessible imaging solutions where and when they are needed most.